---
title: "Weekly Recap | Cybin -3.41%, consensus target above spot"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/302951500.md"
description: "Cybin (HELP) fell 3.41% this week to close at $10.19. The S&P 500 lost 0.47% over the same stretch, leaving the stock roughly 2.94 percentage points behind the benchmark. The move was choppy rather than one-way: Monday (19 Oct) ended at $10.69, Tuesday (20 Oct) pushed as high as $11.74, then the name drifted lower over the next three sessions. Friday (23 Oct) dipped to $9.87 before settling at $10.19. Intraweek amplitude was about 17.76%, meaningfully wider than the prior week."
datetime: "2026-10-24T06:23:48.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/302951500.md)
  - [en](https://longbridge.com/en/news/302951500.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/302951500.md)
generator: "portal-rs"
---

# Weekly Recap | Cybin -3.41%, consensus target above spot

## The Week

Cybin (HELP) fell 3.41% this week to close at $10.19. The S&P 500 lost 0.47% over the same stretch, leaving the stock roughly 2.94 percentage points behind the benchmark. The move was choppy rather than one-way: Monday (19 Oct) ended at $10.69, Tuesday (20 Oct) pushed as high as $11.74, then the name drifted lower over the next three sessions. Friday (23 Oct) dipped to $9.87 before settling at $10.19. Intraweek amplitude was about 17.76%, meaningfully wider than the prior week.

## Key Events

The news flow centred on target price revisions and small- to mid-cap growth narratives. On Wednesday (21 Oct), one item said Helus Pharma Inc.’s 12-month price target had been raised to $43.62, implying 299% upside. The same day, broader industry pieces looked at mid-cap names repositioning around algorithm-driven weakness and hedging flows. Thursday (22 Oct) carried an updated target of $43.59, implying 298% upside. There were no major company-specific product, earnings, or regulatory developments this week, and no material filings after routine disclosures were filtered out.

## Analyst Ratings

A total of 11 brokers rate the stock: 10 at buy and 1 at overweight, with no hold, underweight, or sell ratings. The consensus rating is strong buy, and the consensus target is $41.18, implying about 304% upside from the last close of $10.19. The target range runs from $15.10 to $70.10, a wide spread that points to significant disagreement among analysts. Within the pharmaceutical peer group, the name ranks 36th out of 203.

## The Week Ahead

The coming days are mostly about macro data and the next earnings window. On Tuesday (27 Oct), durable goods orders, new home sales, FHFA house prices, and consumer confidence are due, all of which can shift how small-cap growth names are priced. On 13 Nov (Friday), Cybin is slated to report fiscal 2027 half-year results after the close. That release should give the market a clearer read on profitability and R&D progress.

## In Short

The stock pulled back this week, yet the consensus rating remains strong buy, and the consensus target sits far above spot. Latest-session flow shows large and medium orders as net buyers, while small orders are net sellers, so the tape is not one-sided internally. The company trades at a negative P/E and around 3.08x book value, consistent with a business still in its investment phase. The key tension to watch is whether the half-year update can deliver a more concrete operational story, and how the wide gap between bullish targets and softer price momentum gets resolved.

*This article is generated by LongbridgeAI from market data, for information only and not investment advice.*

### Related Stocks

- [HELP.US](https://longbridge.com/en/quote/HELP.US.md)

## Related News & Research

- [Cybin Executive Chair Eric H. L. So acquires 100,000 common shares worth $1.24 million](https://longbridge.com/en/news/298736201.md)
- [Cybin holds annual, special shareholder meeting; name change set for Oct. 1](https://longbridge.com/en/news/299877253.md)
- [Federal Realty Investment Trust - preferred stock price target increased by 10.58% to $22.12](https://longbridge.com/en/news/302952877.md)
- [Alphabet Inc. $GOOGL Holdings Lifted by CWA Asset Management Group LLC](https://longbridge.com/en/news/302955117.md)
- [HF Sinclair Corporation $DINO Stock Holdings Lowered by Crossmark Global Holdings Inc.](https://longbridge.com/en/news/302956630.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**